The company’s revenue from operations increased 27.8% year-on-year to ₹3,080 crore in Q1 FY27, up from ₹2,410 crore in the same quarter last year.
The pharmaceutical major’s performance also beat CNBC-TV18’s estimates. Net profit was higher than the poll expectation of ₹657 crore, while revenue exceeded the estimated ₹2,911 crore.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) jumped 72.2% year-on-year to ₹1,255 crore from ₹729 crore a year ago. The EBITDA figure was significantly ahead of the CNBC-TV18 poll estimate of ₹915 crore.
The company’s EBITDA margin expanded to 40.8% in Q1 FY27 from 30.2% in the corresponding quarter last year. The margin also surpassed the CNBC-TV18 poll estimate of 31.4%.
The improvement in profitability was led by strong revenue growth and operating performance, with EBITDA margin expansion reflecting better earnings conversion during the quarter.
Divi’s Laboratories is among India’s largest manufacturers of active pharmaceutical ingredients (APIs) and provides contract research and manufacturing services to global pharmaceutical companies.ALSO READ | Mahindra & Mahindra July numbers: SUV volumes grow 20% to 60,048 units, total sales up 26%
First Published: Aug 1, 2026 12:10 PM IST
